Document is current

Documents that mention this clinical trial

Circulating immune cell landscape in patients who had mild ischaemic stroke
https://doi.org/10.1136/svn-2021-001224

Documents that mention this clinical trial

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)
https://doi.org/10.1136/jitc-2021-002374

Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis
https://doi.org/10.1136/jitc-2023-007386

Circulating immune cell landscape in patients who had mild ischaemic stroke
https://doi.org/10.1136/svn-2021-001224

Combination of a therapeutic cancer vaccine targeting the endogenous retroviral envelope protein ERVMER34-1 with immune-oncology agents facilitates expansion of neoepitope-specific T cells and promotes tumor control
https://doi.org/10.1136/jitc-2024-011378

840 A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression
https://doi.org/10.1136/jitc-2021-sitc2021.840

PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations
https://doi.org/10.1136/jitc-2019-000450

727 Resistance to enzalutamide and abiraterone drives tumor phenotypic plasticity and resistance to immune-mediated cytotoxicity
https://doi.org/10.1136/jitc-2021-sitc2021.727

710 Differences in the susceptibility of human small cell lung cancer variants to NK cell-mediated lysis can be overcome with the addition of N803 (IL-15 superagonist)
https://doi.org/10.1136/jitc-2021-sitc2021.710

Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing
https://doi.org/10.1136/jitc-2020-002258